PD60-01 THE IMPACT OF BASELINE HEALTH-RELATED QUALITY OF LIFE ON BIOCHEMICAL RECURRENCE FREE SURVIVAL IN HIGH-RISK PROSTATE CANCER PATIENTS FOLLOWING RADICAL PROSTATECTOMY

Abstract

You have accessJournal of UrologyCME1 May 2022PD60-01 THE IMPACT OF BASELINE HEALTH-RELATED QUALITY OF LIFE ON BIOCHEMICAL RECURRENCE FREE SURVIVAL IN HIGH-RISK PROSTATE CANCER PATIENTS FOLLOWING RADICAL PROSTATECTOMY Thilo Westhofen, Alexander Buchner, Boris Schlenker, Armin Becker, Christian G. Stief, and Alexander Kretschmer Thilo WesthofenThilo Westhofen More articles by this author , Alexander BuchnerAlexander Buchner More articles by this author , Boris SchlenkerBoris Schlenker More articles by this author , Armin BeckerArmin Becker More articles by this author , Christian G. StiefChristian G. Stief More articles by this author , and Alexander KretschmerAlexander Kretschmer More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002645.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Several studies have shown baseline health-related quality of life (HRQOL) to be a valuable prognostic indicator of survival outcomes for various cancer entities in the metastatic setting. To date, there is no evidence regarding the prognostic value of baseline HRQOL for patients undergoing radical prostatectomy (RP) due to localized prostate cancer (PC). The objective of this study was to assess the impact of baseline preoperative HRQOL on survival prognosis for high-risk PC patients following RP. METHODS: 1029 patients with high-risk PC according to NCCN risk stratification and prospectively assessed baseline HRQOL prior RP were included. Patients were stratified by the global health status (GHS) domain of the EORTC QLQ-C30 questionnaire, good general HRQOL was defined as GHS ≥70 based on validated cut-off levels. Subsequently, a propensity score-matched analysis of 636 patients [n=318 (GHS ≥70), n=318 (GHS <70)] was conducted. Primary endpoint was biochemical recurrence-free survival (BRFS), secondary endpoint was metastasis-free survival (MFS). Multivariate Cox regression models were performed to assess prognostic significance of baseline GHS on survival outcomes. Harrell’s discrimination C-index was applied to calculate the predictive accuracy of the model (p <0.05). RESULTS: Median follow-up was 40mo. Applying matching variables age, PSA, pT stage, Gleason grade, positive surgical margin rate, and lymph node involvement, patients subcohorts were well-balanced. 5-yr-BRFS (61% vs. 28%; p <0.001) and 5-yr-MFS (86% vs. 68%; p=0.003) were significantly increased in the GHS≥70 cohort. In multivariate analysis GHS ≥70 was confirmed as an independent predictor for increased BRFS (HR 0.60, 95%CI 0.44–0.82; p=0.013) and MFS (HR 0.51, 95%CI 0.30–0.87; p=0.026). Adding baseline HRQOL to our model improved predictive accuracy of BRFS by 8% (Harrell’s C-index of 0.69 vs 0.65). CONCLUSIONS: Our findings highlight baseline HRQOL to be a valuable and robust prognostic factor for patients with localized high-risk PC prior RP. Baseline good general HRQOL accurately predicts increased BRFS and MFS. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e1024 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Thilo Westhofen More articles by this author Alexander Buchner More articles by this author Boris Schlenker More articles by this author Armin Becker More articles by this author Christian G. Stief More articles by this author Alexander Kretschmer More articles by this author Expand All Advertisement PDF DownloadLoading ...